PepGen Inc. (PEPG)

PepGen shares fell 2.59% to close at $5.26, despite two bullish developments. Wedbush reiterated its Outperform rating and raised its price target to $10, while the company reported favorable early human study data for its myotonic dystrophy type 1 therapy that met study goals. The stock traded in a wide range of $5.11 to $5.90 on heavy volume of over 14.6 million shares, suggesting the positive news was not enough to sustain gains. Despite today's decline, the analyst upgrade and encouraging clinical data point to a positive direction for the stock.

PepGen shares plunged 16.86% to close at $4.61 after the company announced a $125 million common stock offering, a highly dilutive move that overwhelmed positive clinical news. The offering overshadowed interim Phase 2 results showing PGN-EDODM1 achieved 46.5% mean splicing correction and was well tolerated, as well as a prior session in which the stock doubled. The company also reported a third-quarter loss of $0.28 per share, a penny wider than the $0.27 loss analysts expected, adding to the bearish tone. Broader market weakness, with the Nasdaq falling over 200 points on a 0.4% rise in October consumer prices, further pressured the stock. The dominant signal is bearish given the dilutive capital raise and earnings miss.